VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ （5）Known serious medical conditions, including:  │ (5)Known serious medical conditions, including:    │     100 │
│ Cardiovascular: patients with clinically diagnosed │ Cardiovascular: patients with clinically diagnosed │         │
│ cardiac dysfunction (NYHA class III and above),    │ cardiac dysfunction (NYHA class III and above),    │         │
│ hypertrophic obstructive cardiomyopathy,           │ hypertrophic obstructive cardiomyopathy,           │         │
│ clinically significant valvular heart disease,     │ clinically significant valvular heart disease,     │         │
│ acute coronary syndrome within the last 3 months,  │ acute coronary syndrome within the last 3 months,  │         │
│ or percutaneous coronary intervention (PCI), or    │ or percutaneous coronary intervention (PCI), or    │         │
│ coronary artery bypass graft (CABG); or abnormal   │ coronary artery bypass graft (CABG); or abnormal   │         │
│ pre-enrollment ECG test results with clinically    │ pre-enrollment ECG test results with clinically    │         │
│ significant arrhythmias (atrial flutter, atrial    │ significant arrhythmias (atrial flutter, atrial    │         │
│ fibrillation, grade II-III atrioventricular block, │ fibrillation, grade II-III atrioventricular block, │         │
│ etc.); Digestive: a previous diagnosis of various  │ etc.); Digestive: a previous diagnosis of various  │         │
│ types of viral hepatitis that are still in the     │ types of viral hepatitis that are still in the     │         │
│ active phase; abnormal pre-enrollment liver        │ active phase; abnormal pre-enrollment liver        │         │
│ function test results (ALT, AST, GGT, TBIL, or     │ function test results (ALT, AST, GGT, TBIL, or     │         │
│ DBIL 3 times higher than normal, ALB ≤ 30g/L);     │ DBIL 3 times higher than normal, ALB = 30g/L);     │         │
│ gastrectomy and/or gastrojejunostomy;              │ gastrectomy and/or gastrojejunostomy;              │         │
│ gastrointestinal dysfunction; Urinary: pre-        │ gastrointestinal dysfunction; Urinary: pre-        │         │
│ enrollment serum creatinine greater than           │ enrollment serum creatinine greater than           │         │
│ 200μmol/L; clinical diagnosis of renal artery      │ 200umol/L; clinical diagnosis of renal artery      │         │
│ stenosis, isolated kidney, kidney transplantation  │ stenosis, isolated kidney, kidney transplantation  │         │
│ and/or other diseases; Endocrine: type 1 diabetes  │ and/or other diseases; Endocrine: type 1 diabetes  │         │
│ or uncontrolled type 2 diabetes (fasting blood     │ or uncontrolled type 2 diabetes (fasting blood     │         │
│ glucose above 11.1 mmol/L at pre-enrollment);      │ glucose above 11.1 mmol/L at pre-enrollment);      │         │
│ previous diagnosis of hyperthyroidism and failure  │ previous diagnosis of hyperthyroidism and failure  │         │
│ to correct; Respiratory: pulmonary heart disease;  │ to correct; Respiratory: pulmonary heart disease;  │         │
│ chronic obstructive pulmonary disease;             │ chronic obstructive pulmonary disease;             │         │
│ Neuropsychiatric: recent transient ischemic attack │ Neuropsychiatric: recent transient ischemic attack │         │
│ or stroke (within the last 3 months); peripheral   │ or stroke (within the last 3 months); peripheral   │         │
│ or severe autonomic dysfunction; mental or nervous │ or severe autonomic dysfunction; mental or nervous │         │
│ system dysfunction, inability to express desire;   │ system dysfunction, inability to express desire;   │         │
│ known drug or alcohol dependence; Malignancy,      │ known drug or alcohol dependence; Malignancy,      │         │
│ malnutrition, hematopoietic disorders and other    │ malnutrition, hematopoietic disorders and other    │         │
│ serious diseases                                   │ serious diseases                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （3）Voluntarily continues to participate in this  │ (3)Voluntarily continues to participate in this    │      96 │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （4）Diagnosis or suspicion of secondary           │ (4)Diagnosis or suspicion of secondary             │      96 │
│ hypertension                                       │ hypertension                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （4）Voluntarily participates and has signed an    │ (4)Voluntarily participates and has signed an      │      97 │
│ informed consent form                              │ informed consent form                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （3）If a study participant is a woman of          │ (3)If a study participant is a woman of            │      98 │
│ childbearing age, she agrees to use a reliable     │ childbearing age, she agrees to use a reliable     │         │
│ contraceptive method during the trial              │ contraceptive method during the trial              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （1）Completed MTHFR C677T gene polymorphism       │ (1)Completed MTHFR C677T gene polymorphism         │      98 │
│ detection in run-in period or MTHFR C677T genotype │ detection in run-in period or MTHFR C677T genotype │         │
│ already known in advance                           │ already known in advance                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （1）Women who are pregnant and/or lactating; or   │ (1)Women who are pregnant and/or lactating; or     │      98 │
│ women who intend to conceive within a year         │ women who intend to conceive within a year         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （2）History of allergies to enalapril, folic acid │ (2)History of allergies to enalapril, folic acid   │      98 │
│ or other components of the compound drug           │ or other components of the compound drug           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （3）History of adverse reactions or intolerance   │ (3)History of adverse reactions or intolerance to  │      98 │
│ to enalapril or other ACE inhibitors, or drugs or  │ enalapril or other ACE inhibitors, or drugs or     │         │
│ supplements containing folic acid                  │ supplements containing folic acid                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （8）Regular usage of folic acid supplements or    │ (8)Regular usage of folic acid supplements or      │      98 │
│ compounds containing folic acid in the past 3      │ compounds containing folic acid in the past 3      │         │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （2）A diagnosis or previous diagnosis of          │ (2)A diagnosis or previous diagnosis of essential  │      99 │
│ essential hypertension, including anyone currently │ hypertension, including anyone currently taking    │         │
│ taking antihypertensive drugs; or for those who    │ antihypertensive drugs; or for those who have not  │         │
│ have not taken antihypertensive drugs within the   │ taken antihypertensive drugs within the last 2     │         │
│ last 2 weeks, two consecutive examinations were    │ weeks, two consecutive examinations were conducted │         │
│ conducted at least one day apart, and both sitting │ at least one day apart, and both sitting blood     │         │
│ blood pressure (mean value of 3 measurements) met  │ pressure (mean value of 3 measurements) met the    │         │
│ the following criteria: diastolic blood pressure   │ following criteria: diastolic blood pressure (DBP) │         │
│ (DBP) ≥90 mmHg or systolic blood pressure (SBP)    │ =90 mmHg or systolic blood pressure (SBP) =140     │         │
│ ≥140 mmHg (the second blood pressure was measured  │ mmHg (the second blood pressure was measured at    │         │
│ at V1)                                             │ V1)                                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （2）Exhibited good tolerance to enalapril and     │ (2)Exhibited good tolerance to enalapril and good  │      99 │
│ good overall medication compliance (\>80%) in run- │ overall medication compliance (>80%) in run-in     │         │
│ in period or previously exhibited good tolerance   │ period or previously exhibited good tolerance and  │         │
│ and adherence to ACEI drugs in previous medication │ adherence to ACEI drugs in previous medication     │         │
│ history                                            │ history                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （6）Significant signs of abnormalities as seen in │ (6)Significant signs of abnormalities as seen in   │      99 │
│ laboratory tests or physical characteristics,      │ laboratory tests or physical characteristics,      │         │
│ which, at the discretion of the investigators,     │ which, at the discretion of the investigators,     │         │
│ indicates that the patient is experiencing a       │ indicates that the patient is experiencing a       │         │
│ serious illness or, may affect the observation and │ serious illness or, may affect the observation and │         │
│ evaluation of the drug's efficacy or adverse       │ evaluation of the drug's efficacy or adverse       │         │
│ events, or renders the patient unsuitable for      │ events, or renders the patient unsuitable for      │         │
│ participating in this study                        │ participating in this study                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （7）Patients currently taking folate, B12, or B6, │ (7)Patients currently taking folate, B12, or B6,   │      99 │
│ or any compounds containing them, who express an   │ or any compounds containing them, who express an   │         │
│ inability or a refusal to stop usage               │ inability or a refusal to stop usage               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ （9）Participation in a clinical trial for a drug  │ (9)Participation in a clinical trial for a drug    │      99 │
│ that has not yet been officially approved for      │ that has not yet been officially approved for      │         │
│ marketing within one month prior to the first      │ marketing within one month prior to the first      │         │
│ visit                                              │ visit                                              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                   │   Score │
╞════════════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 45 Years                  │ (3)Voluntarily continues to participate in this │      33 │
│                                                    │ study                                           │         │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ for run-in period                                  │ (1)= 45 years old                               │      35 │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Inclusion Criteria for Double-Blind Treatment      │ (4)Diagnosis or suspicion of secondary          │      39 │
│ Period                                             │ hypertension                                    │         │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Participants meeting any of the following criteria │ (3)Voluntarily continues to participate in this │      55 │
│ may not participate in this study                  │ study                                           │         │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ （1）≥ 45 years old                                │ (1)= 45 years old                               │      82 │
╘════════════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═════════════════════╤═══════════════════╤═════════╕
│ Personal Criteria   │ CHIA Criteria     │   Score │
╞═════════════════════╪═══════════════════╪═════════╡
│ （1）≥ 45 years old │ (1)= 45 years old │      82 │
╘═════════════════════╧═══════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 85.61904761904762
OverAll Ratio: 91.30952380952381
